Evaluation of safety, efficacy, and risk factors of different breast reconstruction strategies following polyacrylamide hydrogel removal: A 20-year retrospective cohort study of 436 cases.

BACKGROUND

Globally implemented for breast augmentation, polyacrylamide hydrogel (PAAG) always leads to breast deformity upon its removal. Despite a pressing need for breast reconstruction following PAAG removal to address aesthetic issues, the optimal timing remains controversial.

METHODS

A retrospective cohort study analyzed patients who underwent PAAG removal between 2003 and 2023. They were categorized into three cohorts: immediate (IBR), delayed (DBR), or no breast reconstruction (NBR) post-PAAG removal. Complication rates, re-operation frequencies, risk factors, and BREAST-Q scores were assessed.

RESULTS

A total of 436 breasts were identified and divided into IBR (n = 126), DBR (n = 48), and NBR (n = 262). Complication rates were 50.0 % (IBR), 31.3 % (DBR), and 26.7 % (NBR) (P < 0.001); reoperation rates were 26.2 % (IBR), 18.8 % (DBR), and 13.0 % (NBR) (P = 0.006). IBR showed significantly shorter complication-free survival than NBR (113.38 ± 8.34 vs. 178.21 ± 6.82 months; log-rank P < 0.001). Cox regression identified injection period, aspiration history, Baker grade II/III/IV, glandular infiltration, and IBR as independent predictors of higher postoperative complications. As for the Breast-Q scores, physical well-being was similar across groups. However, NBR scored significantly lower for postoperative sexual well-being (P < 0.001), psychosocial well-being (P < 0.001), and satisfaction with breasts (P = 0.001) compared to both IBR and DBR.

CONCLUSIONS

DBR is a safe and effective solution for secondary breast deformities after PAAG removal. Notably, patients with prolonged injection histories, previous aspiration history, Baker Grade II/III/IV, and MRI evidence of gel infiltration into glandular tissues are at a higher risk for postoperative complications. These findings may be beneficial for optimizing strategies to manage patients with PAAG injections in clinical practice.